PIC/S Draft guidelines – Anexo 22 – Inteligência Artificial

ANVISA
Agência Nacional de Vigilância Sanitária

Histórico

- Avanço rápido das tecnologias digitais e IA exige atualização das diretrizes de GMP.

- Para manter orientações claras, práticas e relevantes para fabricantes e autoridades, decidiu-se, no âmbito do PIC/S:

  - Revisar o Capítulo 4 – Documentação
  - Revisar o Anexo 11 – Sistemas Computadorizados
  - **Criar um novo anexo, o Anexo 22 – Inteligência Artificial**

- Documentos elaborados pelo EMA e PIC/S para garantir alinhamento global.
- Conjunto de documentos fornece estrutura robusta para adoção de TI e IA na fabricação farmacêutica.
- Foco em qualidade do produto e segurança do paciente.
- Consulta pública conjunta da Comissão Europeia e PIC/S.
- Período de consulta: **julho a dezembro de 2025**

PIC/S Anexo 22 – Inteligência Artificial

SUMÁRIO

- Requisitos para uso de IA e machine learning na fabricação de IFAs e medicamentos
- Critérios para seleção, treinamento e validação de modelos de IA
- Definição do uso pretendido e estabelecimento de métricas de desempenho
- Ênfase na qualidade dos dados de treinamento e na gestão dos dados de teste
- Supervisão contínua dos sistemas de IA
- Controle de mudanças e monitoramento do desempenho do modelo
- Procedimentos para revisão humana quando necessário

ANVISA
Agência Nacional de Vigilância Sanitária

PIC/S Anexo 22 – Inteligência Artificial

3 **Document map**

1. Scope
2. Principles
3. Intended Use
4. Acceptance Criteria
5. Test Data
6. Test Data Independency
7. Test Execution
8. Explainability
9. Confidence
10. Operation

ANVISA
Agência Nacional de Vigilância Sanitária

PIC/S Anexo 22 – Escopo

- Aplica-se a todos os sistemas computadorizados usados na fabricação de medicamentos e IFAs que utilizem modelos de IA em **aplicações críticas com impacto direto na segurança do paciente, na qualidade do produto ou na integridade dos dados. (EX: PREDIÇÃO OU CLASSIFICAÇÃO)**

- Oferece orientação adicional ao Anexo 11 para sistemas computadorizados que incorporam modelos de IA.

- Abrange modelos de machine learning cuja funcionalidade resulta de treinamento com dados, e não de programação.

- Aplica-se apenas a modelos estáticos, que não adaptam a performance automaticamente durante o uso incorporando novos dados. **Modelos dinâmicos, que aprendem e se ajustam continuamente, não são cobertos e não devem ser usados em aplicações críticas de GMP.**

ANVISA
Agência Nacional de Vigilância Sanitária

PIC/S Anexo 22 – Escopo

- Abrange apenas modelos com saída determinística, que fornecem o mesmo resultado para entradas idênticas. **Modelos com saída probabilística, que podem variar mesmo com a mesma entrada, não são cobertos e não devem ser usados em aplicações críticas.**

- **Não se aplica à IA Generativa nem a Modelos de Linguagem Extensos (LLMs), que não devem ser usados em aplicações críticas de GMP.** Para usos em aplicações não críticas, a operação deve incluir um profissional qualificado responsável por validar a adequação dos resultados (human-in-the-loop).

ANVISA
Agência Nacional de Vigilância Sanitária

PIC/S Anexo 22 – Escopo

Para aplicações **GMP críticas** com impacto na segurança do paciente

- Determinísticos
- Estáticos

Para aplicações **não GMP críticas**

- Outros modelos são permitidos desde que haja um *human-in-the-loop*

ANVISA
Agência Nacional de Vigilância Sanitária

PIC/S Anexo 22 – Inteligência Artificial

2. Principles

2.1. *Personnel*. In order to adequately understand the intended use and the associated risks of the application of an AI model in a GMP environment, there should be close cooperation between all relevant parties during algorithm selection, and model training, validation, testing and operation. This includes but may not be limited to process subject matter experts (SMEs), QA, data scientists, IT, and consultants. All personnel should have adequate qualifications, defined responsibilities and appropriate level of access.

2.2. *Documentation*. Documentation for activities described in this section should be available and reviewed by the regulated user irrespective of whether a model is trained, validated and tested in-house or whether it is provided by a supplier or service provider.

2.3. *Quality Risk Management* Activities described in this document should be implemented based on the risk to patient safety, product quality and data integrity.

PIC/S Anexo 22 – Inteligência Artificial

3. Intended Use

3.1. *Intended use*. The intended use of a model and the specific tasks it is designed to assist or automate should be described in detail based on an in-depth knowledge of the process the model is integrated in. This should include a comprehensive characterisation of the data the model is intended to use as input and all common and rare variations; i.e. the input sample space. Any limitations and possible erroneous and biased inputs should be identified. A process subject matter expert (SME) should be responsible for the adequacy of the description, and it should be documented and approved before the start of acceptance testing.

3.2. *Subgroups*. Where applicable, the input sample space should be divided into subgroups based on relevant characteristics. Subgroups may be defined by characteristics like the decision output (e.g. 'accept' or 'reject'), process specific baseline characteristics (e.g. geographical site or equipment), specific characteristics in material or product, and characteristics specific to the task being automated (e.g. types and severity of defects).

3.3. *Human-in-the-loop*. Where a model is used to give an input to a decision made by a human operator (human-in-the-loop), and where the effort to test such model has been diminished, the description of the intended use should include the responsibility of the operator. In this case, the training and consistent performance of the operator should be monitored like any other manual process.

PIC/S Anexo 22 – Inteligência Artificial

4. Acceptance Criteria

4.1. *Test metrics*. Suitable, case dependent test metrics, should be defined to measure the performance of the model according to the intended use. As an example, suitable test metrics for a model used to classify products (e.g. 'accept' or 'reject') may include, but may not be limited to, a confusion matrix, sensitivity, specificity, accuracy, precision and/or F1 score.

4.2. *Acceptance criteria*. Acceptance criteria for the defined test metrics should be established by which the performance of the model should be considered acceptable for the intended use. The acceptance criteria may differ for specific subgroups within the intended use. A process subject matter expert (SME) should be responsible for the definition of the acceptance criteria, which should be documented and approved before the start of acceptance testing.

4.3. *No decrease*. The acceptance criteria of a model, should be at least as high as the performance of the process it replaces. This implies, that the performance should be known for the process which is to be replaced by a model (see Annex 11 2.7).

PIC/S Anexo 22 – Inteligência Artificial

5. Test Data

5.1. *Selection*. Test data should be representative of and expand the full sample space of the intended use. It should be stratified, include all subgroups, and reflect the limitations, complexity and all common and rare variations within the intended use of the model. The criteria and rationale for selection of test data should be documented.

5.2. *Sufficient in size*. The test dataset, and any of its subgroups, should be sufficient in size to calculate the test metrics with adequate statistical confidence.

5.3. *Labelling*. The labelling of test data should be verified following a process that ensures a very high degree of correctness. This may include independent verification by multiple experts, validated equipment or laboratory tests.

5.4. *Pre-processing*. Any pre-processing of the test data, e.g. transformation, normalisation, or standardisation, should be pre-specified and a rationale should be provided, that it represents intended use conditions.

5.5. *Exclusion*. Any cleaning or exclusion of test data should be documented and fully justified.

5.6. *Data generation*. Generation of test data or labels, e.g. by means of generative AI, is not recommended and any use hereof should be fully justified.

PIC/S Anexo 22 – Inteligência Artificial

6. Test Data Independency

6.1. *Independence*. Effective measures consisting of technical and/or procedural controls should be implemented to ensure the independency of test data, i.e. that data which will be used to test a model, is not used during development, training or validation of the model. This may be by capturing test data only after completion of training and validation, or by splitting test data from a complete pool of data before training has started.

6.2. *Data split*. If test data is split from a complete pool of data before training of the model, it is essential that employees involved in the development and training of the model have never had access to the test data. The test data should be protected by access control and audit trail functionality logging accesses and changes to these. There should be no copies of test data outside this repository.

6.3. *Identification*. It should be recorded which data has been used for testing, when and how many times.

6.4. *Physical objects*. When test data originates from physical objects, it should be ensured, that the objects used for the final test of the model have not previously been used to train or validate the model, unless features are independent.

6.5. *Staff independency*. Effective procedural and/or technical controls should be implemented to prevent staff members who have had access to test data from being involved in training and validation of the same model. In organisations where it is impossible to maintain this independency, a staff member who might have had access to test data for a model, should only have access to training and validation of the same model when working together (in pair) with a colleague who has not had this access (4-eyes principle).

PIC/S Anexo 22 – Inteligência Artificial

7. Test Execution

7.1. *Fit for intended use*. The test should ensure that a model is fit for intended use and is 'generalising well', i.e. that the model has a satisfactory performance with new data from the intended use. This includes detecting possible over- or underfitting of the model to the training data.

7.2. *Test plan*. Before the test is initiated, a test plan should be prepared and approved. It should contain a summary of the intended use, the pre-defined metrics and acceptance criteria, a reference to the test data, a test script including a description of all steps necessary to conduct the test, and a description of how to calculate the test metrics. A process subject matter expert (SME) should be involved in developing the plan.

7.3. *Deviation*. Any deviation from the test plan, failure to meet acceptance criteria, or omission to use all test data should be documented, investigated, and fully justified.

7.4. *Test documentation*. All test documentation should be retained along with the description of the intended use, the characterisation of test data, the actual test data, and where relevant, physical test objects. In addition, documentation for access control to test data and related audit trail records, should be retained similarly to other GMP documentation.

PIC/S Anexo 22 – Inteligência Artificial

8. Explainability

8.1. *Feature attribution*. During testing of models used in critical GMP applications, systems should capture and record the features in the test data that have contributed to a particular classification or decision (e.g. rejection). Where applicable, techniques like feature attribution (e.g. SHAP values or LIME) or visual tools like heat maps should be used to highlight key factors contributing to the outcome.

8.2. *Feature justification*. In order to ensure that a model is making decisions based on relevant and appropriate features and based on risk, a review of these features should be part of the process for approval of test results.

PIC/S Anexo 22 – Inteligência Artificial

9. Confidence

9.1. *Confidence score*. When testing a model used to predict or classify data, the system should, where applicable, log the confidence score of the model for each prediction or classification outcome.

9.2. *Threshold*. Models used to predict or classify data should have an appropriate threshold setting to ensure predictions or classifications are made only when suitable. If the confidence score is very low, it should be considered whether the model should flag the outcome as 'undecided', rather than making potentially unreliable predictions or classifications.

PIC/S Anexo 22 – Inteligência Artificial

10. Operation

10.1. *Change control*. A tested model, the system it is implemented in, and the whole process it is automating or assisting should be put under change control before it is deployed in operation. Any change to the model itself, the system, or the process in which it is used, including any change to physical objects the model is using as input, should be documented and evaluated to determine if the model needs to be retested. Any decision not to conduct such retest should be fully justified.

10.2. *Configuration control*. A tested model should be put under configuration control before being deployed in operation, and effective measures should be used to detect any unauthorised change.

10.3. *System performance monitoring*. The performance of a model as defined by its metrics should be regularly monitored to detect any changes in the computerised system (e.g. deterioration or change of a lighting condition).

10.4. *Input sample space monitoring*. It should be regularly monitored whether the input data are still within the model sample space and intended use. Metrics should be defined for monitoring any drift in the input data.

10.5. *Human review*. When a model is used to give an input to a decision made by a human operator (human-in-the-loop), and where the effort to test such model has been diminished, records should be kept from this process. Depending on the criticality of the process and the level of testing of the model, this may imply a consistent review and/or test of every output from the model, according to a procedure.

ANVISA
Agência Nacional de Vigilância Sanitária

Obrigada!

gimed@anvisa.gov.br
julia.diniz@anvisa.gov.br

ANVISA
Agência Nacional de Vigilância Sanitária